University of Miami — Biomedical Watch V2

Traitements12programmes

Essais6liés

Publications0liées

SourceDBlocale

Traitements

12

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CAPTURE-ALS — Clinical Procedures to Support Research in ALSDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	À vérifier	United States	À vérifier
CetirizineThe purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.	SEP	Phase 3	Immunomodulation	United States	À vérifier
Gorbly Compression DeviceProspective cohort study. All patients presenting for percutaneous abdomino-pelvic soft tissue ablation, biopsy, or drainage performed under the care of Dr. Issam Kably will become part of the study population. Based on prior imaging and/or imaging at the time of the procedure, patients will fall into two groups, those for whom no compression is necessary to complete the procedure and those for whom compression may provide benefit. These would be selected based on Dr. Kably's experience as a practicing academic, fellowship-trained, and CAQ'ed interventional radiologist. The latter group would then further subdivide into those who give consent for use of the compression device and those who do not consent. Results of each group would be measured including the following: termination versus successful completion of the procedure; adverse events including bleeding or damage to surrounding structures necessitating further medical or surgical intervention.	Cancer	Non applicable	À vérifier	United States	À vérifier
PGB2 — Phenotype, Genotype and Biomarkers 2Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Traitement symptomatique	United States, South Africa	À vérifier
Phenotype, Genotype & Biomarkers in ALS and Related DisordersDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	À vérifier	United States, Germany, South Africa	À vérifier
TRIAL READY (Clinical Trial Readiness)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	À vérifier	United States	À vérifier
CAPTURE-ALS — Clinical Procedures to Support Research in ALSDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	À vérifier	United States	À vérifier
TRIAL READY (Clinical Trial Readiness)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	À vérifier	United States	À vérifier
Phenotype, Genotype & Biomarkers in ALS and Related DisordersDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	À vérifier	United States, Germany, South Africa	À vérifier
PGB2 — Phenotype, Genotype and Biomarkers 2Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Traitement symptomatique	United States, South Africa	À vérifier
CetirizineThe purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.	SEP	Phase 3	Immunomodulation	United States	À vérifier
Gorbly Compression DeviceProspective cohort study. All patients presenting for percutaneous abdomino-pelvic soft tissue ablation, biopsy, or drainage performed under the care of Dr. Issam Kably will become part of the study population. Based on prior imaging and/or imaging at the time of the procedure, patients will fall into two groups, those for whom no compression is necessary to complete the procedure and those for whom compression may provide benefit. These would be selected based on Dr. Kably's experience as a practicing academic, fellowship-trained, and CAQ'ed interventional radiologist. The latter group would then further subdivide into those who give consent for use of the compression device and those who do not consent. Results of each group would be measured including the following: termination versus successful completion of the procedure; adverse events including bleeding or damage to surrounding structures necessitating further medical or surgical intervention.	Cancer	Non applicable	À vérifier	United States	À vérifier

Essais cliniques

6

Molécule	Indication / population	Phase	NCT	Titre	Statut
Gorbly Compression Device	Cancer	Non applicable	NCT02578667	Gorbly Compression Device for Use in Image-guided Procedures	WITHDRAWN
Cetirizine	SEP	Phase 3	NCT07472413	Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project	NOT_YET_RECRUITING
PGB2 — Phenotype, Genotype and Biomarkers 2	Sclérose latérale amyotrophique	À vérifier	NCT04875416	PGB2 — Phenotype, Genotype and Biomarkers 2	ACTIVE_NOT_RECRUITING
Phenotype, Genotype & Biomarkers in ALS and Related Disorders	Sclérose latérale amyotrophique	À vérifier	NCT02327845	Phenotype, Genotype & Biomarkers in ALS and Related Disorders	ACTIVE_NOT_RECRUITING
TRIAL READY (Clinical Trial Readiness)	Sclérose latérale amyotrophique	À vérifier	NCT03912987	TRIAL READY (Clinical Trial Readiness)	ACTIVE_NOT_RECRUITING
CAPTURE-ALS — Clinical Procedures to Support Research in ALS	Sclérose latérale amyotrophique	À vérifier	NCT03489278	CAPTURE-ALS — Clinical Procedures to Support Research in ALS	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.